2026 Q3 Portfolio Activity
In 2026 Q3, Aisling Capital Management LP maintained a portfolio of 14 distinct positions. They heavily accumulated shares in COMPASS PATHWAYS PLC, increasing the position by 20.9%. The fund also reduced its exposure to BRIDGEBIO PHARMA INC by 32.7%.
Position History
hover any row below to update
Loading…
Total Positions
14
Quarter
2026 Q3
Top Holding
BBIO (67.9%)
Top 10 Concentration
98.5%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-14 of 14
Aisling Capital Management LP Full Holdings List — 2026 Q3
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
BBIO
BRIDGEBIO PHARM...
|
Healthcare | 67.92% | 72.48% |
#1
Prev: #1
|
6.0 |
—
|
-1,500,000 | -32.7% |
P
S
|
3,089,611 | $203,296,404 | 2019 Q2 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 8.27% | 6.10% |
#2
1
Prev: #3
|
5.8 |
—
|
no change | no change |
P
S
|
1,316,806 | $24,755,953 | 2020 Q1 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 7.20% | 4.30% |
#3
1
Prev: #4
|
6.4 |
—
|
300,000 | 20.9% |
P
S
|
1,732,336 | $21,550,260 | 2023 Q3 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
GLUE
MONTE ROSA THER...
|
Healthcare | 6.20% | 7.98% |
#4
2
Prev: #2
|
4.0 |
—
|
no change | no change |
P
S
|
1,555,664 | $18,559,072 | 2021 Q2 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 3.41% | 3.58% |
#5
Prev: #5
|
2.4 |
—
|
-20,000 | -3.5% |
P
S
|
548,919 | $10,215,383 | 2024 Q3 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
URGN
UROGEN PHARMA L...
|
Healthcare | 1.47% | 0.84% |
#6
2
Prev: #8
|
1.6 |
—
|
no change | no change |
P
S
|
108,000 | $4,388,040 | 2025 Q4 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
BBOT
BRIDGEBIO ONCOL...
|
Healthcare | 1.38% | 1.64% |
#7
1
Prev: #6
|
1.6 |
—
|
no change | no change |
P
S
|
1,018,018 | $4,137,874 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
EPRX
EUPRAXIA PHARMA...
|
Healthcare | 0.99% | 0.46% |
#8
3
Prev: #11
|
1.4 |
—
|
no change | no change |
P
S
|
325,000 | $2,957,500 | 2026 Q1 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
BMEA
BIOMEA FUSION I...
|
Healthcare | 0.92% | 0.64% |
#9
Prev: #9
|
1.4 |
—
|
no change | no change |
P
S
|
2,048,757 | $2,742,847 | 2021 Q2 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
ACRS
ACLARIS THERAPE...
|
Healthcare | 0.76% | 0.49% |
#10
Prev: #10
|
1.3 |
—
|
no change | no change |
P
S
|
434,455 | $2,285,233 | 2018 Q4 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
SRRK
SCHOLAR ROCK HL...
|
Healthcare | 0.68% | 0.90% |
#11
4
Prev: #7
|
0.3 |
—
|
-35,000 | -45.4% |
P
S
|
42,031 | $2,030,938 | 2025 Q3 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
VTVT
VTV THERAPEUTIC...
|
Healthcare | 0.61% | 0.40% |
#12
Prev: #12
|
2.2 |
—
|
8,775 | 17.5% |
P
S
|
58,775 | $1,812,621 | 2026 Q2 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
MRKR
MARKER THERAPEU...
|
Healthcare | 0.12% | 0.10% |
#13
Prev: #13
|
1.0 |
—
|
no change | no change |
P
S
|
325,370 | $348,146 | 2023 Q2 | 13F Filing | 2026-09-30 | 2026-11-12 | |||
|
OKUR
ONKURE THERAPEU...
|
Healthcare | 0.08% | 0.09% |
#14
Prev: #14
|
1.0 |
—
|
no change | no change |
P
S
|
88,607 | $241,454 | 2024 Q4 | 13F Filing | 2026-09-30 | 2026-11-12 |
Showing 1-14 of 14 holdings